Real-world evidence in NSCLC asset development: Global trials, treatment patterns, and predictive models

Emilie Scherrer is the Senior Director and Head of Outcomes Research at Tempus and is a member of the RWE Alliance. Emilie was previously the Global Director of Health Economics and Outcomes Research at Seagen. She has worked in biopharma (Amgen, Merck, Seagen, Pfizer) for a decade in roles across HEOR and RWE. She has extensive knowledge in designing and executing non-interventional, observational research studies for external dissemination (40+ publications) and regulatory submissions. Emilie earned an undergraduate degree from USC and a Masters in Health Economics from the London School of Economics / LSHTM.

Maria Berezina is the VP of Real World Data Analytics at Tempus, where she oversees clinical data structuring, data model development, and RWD/RWE analytics. With a decade of experience in oncology analytics, she provides business and research insights to large pharmaceutical companies, biotechs, start-ups, investment funds, and insurance providers. Over the past five years, she has built and led RWD analytics and data science teams, overseeing numerous retrospective studies for life science partners. Her blend of technical expertise, deep knowledge of clinical care in oncology, and experience in RWE generation ensures that Tempus' multi-modal RWD product aligns with life science research goals. She holds a bachelor's degree in Electrical Engineering from the University of Massachusetts Lowell and a doctoral degree in Biomedical Engineering from the Harvard-MIT Division of Health Science and Technology.

Dr. Toyoki Moribe is the Director of the Medical Strategy Department at GenMine Labs Corp. He brings over 10 years of experience in genetic diagnosis R&D, alongside more than 15 years in Medical Affairs within the pharmaceutical and diagnostics industries. Prior to joining GenMine Labs, he spearheaded medical strategic initiatives as the Head of Hematology Medical at Bristol Myers Squibb and Pfizer, overseeing products from pre-launch to post-launch phases. Additionally, he has led the discovery of novel genetic diagnostic markers and the development of in vitro diagnostics (IVDs) as a research scientist. Dr. Moribe holds a Master’s degree in Science from Nagoya University and a PhD in Medicine from Osaka University.

Shijun Jo is Head of Life Science Solution at SB TEMPUS, where he leads the delivery of multimodal real-world data and analytics services to pharmaceutical and life sciences companies in Japan. Prior to joining SB TEMPUS, he worked at ITOCHU Corporation, where he was responsible for sales of active pharmaceutical ingredients and drug products to pharmaceutical companies, as well as new business development. He later joined CureApp, a digital therapeutics startup, where he led business partnerships with multiple pharmaceutical companies and, as Head of Overseas Business, drove product development and strategic partnerships for the U.S. market.

Shelley is a PhD-level computational biologist with a history in both academia and industry and a demonstrated ability to deliver valuable insights and action-oriented solutions to complex biological problems via bioinformatics, genomic data analysis, databases, software engineering, and advanced data-driven methods. Ultimately, she is driven by the goal of improving the lives of patients with cancer and other complex diseases through genomics and data analytics.